Amanda J. Redig, Ph.D.
Affiliations: | 2009 | Integrated Graduate Program in the Life Sciences | Northwestern University, Evanston, IL |
Area:
Molecular BiologyGoogle:
"Amanda Redig"Parents
Sign in to add mentorLeonidas C. Platanias | grad student | 2009 | Northwestern | |
(The protein kinase C (PKC) family and the regulation of hematopoiesis.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Guerra SL, Maertens O, Kuzmickas R, et al. (2020) A Deregulated HOX Gene Axis Confers an Epigenetic Vulnerability in KRAS-Mutant Lung Cancers. Cancer Cell |
Oxnard GR, Hu Y, Mileham KF, et al. (2018) Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib. Jama Oncology |
Bahcall M, Awad MM, Sholl LM, et al. (2018) Amplification of wild type KRAS imparts resistance to crizotinib in MET exon 14 mutant non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
Awad MM, Bahcall M, Sholl LM, et al. (2018) Mechanisms of acquired resistance to MET tyrosine kinase inhibitors (TKIs) in MET exon 14 (METex14) mutant non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 36: 9069-9069 |
Köhler J, Gokhale PC, Li J, et al. (2018) Abstract 5467: Efficacy of the ERK inhibitor LY3214996 and the PI3K/mTOR inhibitor LY3023414 in patient-derived RAS-mutant NSCLC models Cancer Research. 78: 5467-5467 |
Redig AJ. (2017) Raising the bar: the future of EGFR inhibition in non-small lung cancer. Translational Lung Cancer Research. 6: S58-S61 |
Krall EB, Wang B, Munoz DM, et al. (2017) Correction: KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer. Elife. 6 |
Kosaka T, Tanizaki J, Paranal R, et al. (2017) Response heterogeneity of EGFR and HER2 exon 20 insertions to covalent EGFR and HER2 inhibitors. Cancer Research |
Krall EB, Wang B, Munoz DM, et al. (2017) KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer. Elife. 6 |
Krall EB, Wang B, Munoz DM, et al. (2017) Author response: KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer Elife |